RoosterBio recently hosted a webinar called “Planning a Successful MSC Therapy for Rapid COVID Response” to address challenges that mesenchymal stem/stromal cell (MSC) therapy developers might face to manufacture sufficient doses to treat COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) or other related indications.
Aspire Health Science Receives IND Approval to Test ACT-20 Cellular Therapy Against COVID-19 Pneumonia
Aspire Health Science Announces U.S. FDA approval of IND application regarding testing proprietary ACT-20 Cellular Therapy against COVID-19 Pneumonia and a partnering opportunity for Biotech Companies and Investors.
COVID-19 Pipelines – Cell Therapies, Diagnostics, Treatments, & Vaccines
While there is not yet an approved treatment for COVID-19, scientific, medical and regulatory agencies are making heroic efforts to bring out new medicines. Numerous COVID-19 product categories have emerged, including vaccines, antibodies, antivirals, repurposed drugs, RNA-based drugs, and cell-based therapies, as well as other approaches, such as enzymes, peptides and glycoproteins. [Read more…]
Regenerative Medicine (RM) Companies Are Surging During COVID-19
It’s official. Regenerative medicine (RM) companies are surging during COVID-19.
There are now 800+ companies developing regenerative medicine products for therapeutic use in humans — hundreds of which are contributing toward the management of the global COVID-19 pandemic. [Read more…]
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients
Miami, FL (May 27, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today a health update for two critically ill COVID-19 patients who were treated at Landmark Hospital in Athens, GA with the Company’s Organicell Flow product. These patients were treated under the two recently approved Emergency Compassionate Use Investigational New Drug applications (eINDs) by the U.S. Food and Drug Administration (FDA). [Read more…]